Concord Biotech

Concord Biotech EBIT Margin

The EBIT Margin (Operating Margin) of Concord Biotech (CONCORDBIO.NS) as of Oct 18, 2026 is 32.70 %. In the previous year, EBIT Margin (Operating Margin) was 50.16 % — a change of -34.81% (lower).

EBIT Margin

32.70 %

YoY

-34.81%

Last updated:

EBIT Margin (Operating Margin) of Concord Biotech is 2026 32.70 % . EBIT Margin (Operating Margin) of Concord Biotech was 2025 50.16 % . It decreases by -34.81% lower compared to the previous year.

Concord Biotech's operating (EBIT) margin stands at 32.7%, down from 58.4% several years earlier.

The Concord Biotech EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2020
60.86 INR
Jan 1, 2021
69.71 INR
Jan 1, 2022
58.38 INR
Jan 1, 2023
60.71 INR
Jan 1, 2024
51.26 INR
Jan 1, 2025
50.16 INR
Jan 1, 2026
32.70 INR
The Concord Biotech EBIT Margin history
YEAREBIT MarginYoY
32.70 %-34.81%
50.16 %-2.13%
51.26 %-15.58%
60.71 %+3.99%
58.38 %-16.24%
69.71 %+14.53%
60.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Concord Biotech Stock analysis

What does Concord Biotech do? Concord Biotech Ltd is a pharmaceutical company headquartered in Ahmedabad, India. It operates in the Health Care sector with a focus on Pharmaceuticals. The company went public via an IPO on August 18, 2023. Concord Biotech develops and manufactures active pharmaceutical ingredients (APIs) using fermentation and semi-synthetic processes. It produces finished formulations and APIs for therapeutic areas including immunosuppressants, anti-bacterial, oncology, and anti-fungal treatments. The company's API portfolio includes Mycophenolate Mofetil, Cyclosporine, Vancomycin Hydrochloride, and others. It also has a pipeline of API products under development such as Polymyxin B and Fidaxomicin. Concord Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Concord Biotech stock

EBIT Margin (Operating Margin) of Concord Biotech is 32.70 % in 2026.

EBIT Margin (Operating Margin) of Concord Biotech changed from 50.16 % to 32.70 %, representing a -34.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Concord Biotech since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Concord Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Concord Biotech

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Concord Biotech